Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678998 | 0.86 | KMT2A (0.72) | KMT2AMEN1POLBCASP6BRD4 | |
| SCHEMBL2494879 | 0.85 | KMT2A (0.53) | KMT2AMEN1POLBCASP6BRD4 | |
| SCHEMBL1464852 | 0.84 | KMT2A (0.59) | KMT2AMEN1BRD4LMNAGAA | |
| SCHEMBL1480710 | 0.82 | KMT2A (0.39) | KMT2AMEN1POLBCASP6BRD4 | |
| SCHEMBL75146 | 0.82 | KMT2A (0.50) | KMT2AMEN1POLBCASP6BRD4 | |
| SCHEMBL2502271 | 0.79 | BRD4 (0.57) | KMT2AMEN1POLBCASP6BRD4 | |
| SCHEMBL5674361 | 0.79 | KMT2A (0.48) | KMT2AMEN1POLBCASP6BRD4 | |
| SCHEMBL1588395 | 0.78 | KMT2A (0.47) | KMT2AMEN1POLBCASP6LMNA | |
| SCHEMBL11042940 | 0.77 | KMT2A (0.50) | KMT2AMEN1LMNAGAAALDH1A1 | |
| SCHEMBL1796721 | 0.76 | KMT2A (0.51) | KMT2AMEN1POLBCASP6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338590-B2 | Substituted oxindole derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2012-12-25 | — | — | US | disclosed |
| US-8202870-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20120136001-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO. KG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-7951807-B2 | Substituted oxindol derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090215790-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1866304-A2 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1773814-B1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO KG (DE) | 2007-11-07 | — | — | EP | disclosed |
| EP-1773814-A2 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | Abbott GmbH & Co. KG (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006100081-A2 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006005609-A2 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO.KG (DE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | OXTR, AVPR2, AVPR1B | KMT2A 4350/4885MEN1 331/4885POLB 4663/4885 |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | OXTR, AVPR2, AVPR1B | KMT2A 4284/4885MEN1 360/4885POLB 4637/4885 |
| US-20090215790-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | KMT2A 4000/4885MEN1 176/4885POLB 4240/4885 |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | KMT2A 3892/4885MEN1 238/4885POLB 4548/4885 |
| US-20120136001-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | OXTR, AVPR2, AVPR1B | KMT2A 3892/4885MEN1 238/4885POLB 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.